Drugs / BO-653
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00055510 | — | atherosclerosis, coronary restenosis, vascular occlusion disorder | Chugai Pharma USA | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BO-653 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00055510 ↗ |
| Action | Inhibit | “an investigational inhibitor of LDL cholesterol oxidation” NCT00055510 ↗ |
| Modality | Small molecule | — CHEMBL104186 ↗ |
| Route | Oral | “when given orally twice a day” NCT00055510 ↗ |